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ARTICLE
HHEX is a transcriptional regulator of the
VEGFC/FLT4/PROX1 signaling axis during
vascular development
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Formation of the lymphatic system requires the coordinated expression of several key
regulators: vascular endothelial growth factor C (VEGFC), its receptor FLT4, and a key
transcriptional effector, PROX1. Yet, how expression of these signaling components is
regulated remains poorly understood. Here, using a combination of genetic and molecular
approaches, we identify the transcription factor hematopoietically expressed homeobox
(HHEX) as an upstream regulator of VEGFC, FLT4, and PROX1 during angiogenic sprouting
and lymphatic formation in vertebrates. By analyzing zebraﬁsh mutants, we found that hhex
is necessary for sprouting angiogenesis from the posterior cardinal vein, a process required
for lymphangiogenesis. Furthermore, studies of mammalian HHEX using tissue-speciﬁc
genetic deletions in mouse and knockdowns in cultured human endothelial cells reveal
its highly conserved function during vascular and lymphatic development. Our ﬁndings that
HHEX is essential for the regulation of the VEGFC/FLT4/PROX1 axis provide insights into
the molecular regulation of lymphangiogenesis.
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Transcriptional regulation of endothelial cell fate andbehavior is key to shape and maintain a competentvascular network. During development, lymphatic endo-
thelial cells (LECs) have been reported to arise from a speciﬁc
subset of vein endothelial cells and require the VEGFC/FLT4/
PROX1 signaling axis for their migration, proliferation, and
differentiation1–3. However, how the expression of these signaling
components is regulated remains poorly understood. Of the
transcription factor genes regulating endothelial cell physiology,
hematopoietically expressed homeobox (hhex), also known
as proline rich homeodomain (prh), is one of the earliest
expressed by endothelial and hematopoietic precursors in
frogs4, zebraﬁsh5, and mice6. In zebraﬁsh, Hhex can positively
regulate endothelial and blood cell differentiation5; however,
analysis of a deletion allele which lacks hhex, as well as several
other genes, suggests that Hhex is not essential for early endo-
thelial and blood cell differentiation5. In mouse, Hhex mutants
have multiple developmental defects including marked abnorm-
alities in heart, liver, thyroid, and vascular formation7,8.
In human endothelial and leukemic cells, HHEX is known to
be a direct transcriptional regulator of VEGFA, VEGFR1, and
VEGFR29. However, its precise function during angiogenesis
and lymphangiogenesis remains unclear.
Through TAL effector nuclease (TALEN) mutagenesis, gene
expression analysis, transplantation experiments and endothelial-
speciﬁc overexpression, we show that in zebraﬁsh, Hhex functions
cell-autonomously in endothelial cells to regulate sprouting
angiogenesis from the posterior cardinal vein (PCV) and sub-
sequent lymphangiogenesis. We further show through knock-
down experiments in vitro and genetic deletions in vivo that this
crucial role during angiogenesis and lymphangiogenesis is con-
served in mammals. Overall, our data show that HHEX controls
blood vessel and lymphatic vessel formation by regulating the
VEGFC/FLT4/PROX1 signaling axis.
Results
Zebraﬁsh hhex mutants exhibit sprouting defects from the
PCV. HHEX is a transcription factor composed of a proline-rich
domain and a highly conserved homeodomain10. Previously,
we used the γ-ray-induced deletion allele b16 to investigate
hhex function in zebraﬁsh10. However, the b16 deletion affects
the lower telomeric region of chromosome 12 and removes hhex
and cyclops (ndr2) as well as at least 14 other genes11. b16
mutants display pleiotropic phenotypes including cyclopia and
curvature of the body axis12. Therefore, in order to determine
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Fig. 1 Zebraﬁsh hhexmutants lack sprouting angiogenesis from the posterior cardinal vein. a Schematic representation of Hhex. Hhex, 228 amino acids (aa)
long, is composed of a proline-rich domain (4–113 aa) and a homeodomain (116–175 aa). b Alignment of partial Hhex homeodomain sequence in wild-type
(WT), and two mutant alleles, hhexs721 and hhexs722. The hhexs721 allele contains a 10 bp insertion leading to a premature stop codon within the
homeodomain coding region, whereas the hhexs722 allele lacks amino acids R149 to A151. c, d Trunk vasculature of Tg(−5.2lyve1b:DsRed); hhex+/+ and
hhex−/− embryos at 48 hpf. hhex mutant trunks exhibit a defect in sprouting angiogenesis from the posterior cardinal vein (PCV) (arrowheads point to tip
cells sprouting from the PCV; asterisks indicate lack of tip cells sprouting from the PCV). e, f Trunk vasculature of Tg(−5.2lyve1b:DsRed); hhex+/+ and
hhex−/− larvae at 5 dpf. hhex mutant trunks exhibit a defect in the formation of the venous intersegmental vessels (vISVs), the thoracic duct (TD)
lymphatic vessel, and the dorsal longitudinal lymphatic vessel (DLLV) (arrowhead points to a vISV; arrows point to the ventrally positioned TD and dorsally
positioned DLLV; asterisks indicate lack of these structures). g, h Brightﬁeld lateral views of hhex+/+ and hhex−/− larvae at 5 dpf. Mutant larvae exhibit
pericardial edema (arrowhead). Scale bars: 100 μm
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more precisely the function of Hhex during zebraﬁsh develop-
ment, we generated hhex mutants using TALENs13. TALEN
pairs were designed against the homeodomain sequence
(Fig. 1a) and two different alleles were recovered: hhexs721
which carries a 10 bp insertion leading to a premature stop
codon and hhexs722, an in-frame deletion of three amino acids
(R149 to A151) in the second helix of the DNA-binding domain
important for the stability of the protein during its interaction
with DNA14 (Fig. 1b). In all our assays, both alleles exhibit the
same phenotype.
In the zebraﬁsh axial vasculature, sprouting angiogenesis
occurs in two waves. Sprouting from the dorsal aorta starts at
20 hours post fertilization (hpf) to give rise to arterial
intersegmental vessels (aISVs)15. Subsequently, endothelial
sprouting from the PCV occurs between 32 and 36 hpf15 and
this process gives rise to both venous ISVs (vISVs) and LECs16.
aISVs appear to form normally in hhex mutants (Supplementary
Fig. 1c, d); however, using the Tg(−5.2lyve1b:DsRed) line to
visualize the venous and lymphatics endothelial cells, we observed
that hhex mutants lack most sprouting vessels from the PCV
(Fig. 1c, d). Time-lapse imaging of wild-type and mutant embryos
show that while sprouting angiogenesis from the PCV is clearly
observed in wild-type siblings between 32 and 36 hpf, no cell
migration from the PCV is visible in hhex mutants at least until
48 hpf (Supplementary Movies 1, 2). Furthermore, at 5 days
post fertilization (dpf), hhex mutants exhibit pericardial edema
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Fig. 2 The Vegfc/Flt4 pathway is affected in zebraﬁsh hhex mutants. a–d Whole-mount in situ hybridization showing ﬂt4 (a, b) and vegfc (c, d) expression
in 24 hpf hhex+/+ and hhex−/− embryos. At 24 hpf, hhex mutants exhibit decreased ﬂt4 expression (asterisks), whereas vegfc expression in the PCV
appears to be slightly increased (arrowheads). e–h Whole-mount in situ hybridization showing ﬂt4 (e, f) and vegfc (g, h) expression at 32 hpf in hhex+/+
and hhex−/− embryos. At 32 hpf, hhex mutants exhibit a strong decrease in ﬂt4 expression (asterisks), whereas vegfc expression is clearly increased
in the PCV (arrowheads). x/y: number of embryos showing representative phenotype (x), number of embryos examined (y). i Trunk vasculature of 5 dpf
Tg(kdrl:EGFP); hhex−/− injected, or not, with full-length human FLT4 mRNA. hhex mutants exhibit partial rescue of their vISVs at 5 dpf (arrowheads
point to vISVs). j Quantiﬁcation of vISVs across 10 somites in 5 dpf non-injected hhex−/− (n= 6) and FLT4 mRNA-injected hhex−/− (n= 8). k Trunk
lymphatic vasculature of 5 dpf Tg(−5.2lyve1b:DsRed); hhex−/− injected, or not, with full-length human FLT4 mRNA. hhex mutants exhibit partial rescue
of their TD at 5 dpf (arrowheads point to vISVs and arrow points to TD). l Quantiﬁcation of TD extensions across 10 somites in 5 dpf non-injected hhex−/−
(n= 6) and FLT4 mRNA-injected hhex−/− (n= 7). Values represent means ± s.e.m. ****P≤ 0.0001 and *P≤ 0.05 by t-test. Scale bars: 50 μm
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(Fig. 1g, h), a near absence of vISVs, a complete loss of trunk
lymphatic vessels, and a strong reduction of facial lymphatic
vessels (Fig. 1e, f, Supplementary Fig. 1e–i, Supplementary Fig. 2).
Altogether, these observations indicate that Hhex regulates the
earliest step of sprouting angiogenesis and lymphangiogenesis
from the PCV.
Vegfc/Flt4/Prox1 signaling axis is affected in hhex mutants.
Angiogenesis is mostly regulated by vascular endothelial growth
factors (VEGFs) and their receptors (VEGFRs). Similar to hhex
mutants, vegfc and ﬂt4 (also known as vegfr3) mutants also fail to
initiate sprouting angiogenesis and lymphangiogenesis from the
PCV16–19. Additionally, hhex mutants exhibit a delayed forma-
tion of the primordial hindbrain channels at 26 hpf (Supple-
mentary Fig. 1a, b), similar to vegfc and ﬂt4 mutants17,18.
Therefore, we decided to examine the Vegfc/Flt4 signaling
pathway in hhex mutants. We ﬁrst assessed vegfc and ﬂt4
expression at 24 and 32 hpf by whole-mount in situ hybridization
(Fig. 2a–h). At 24 hpf, hhex mutants exhibit decreased ﬂt4
expression while vegfc was slightly increased and ectopically
expressed in the PCV (Fig. 2a–d). These changes were more
pronounced at 32 hpf, as ﬂt4 expression was greatly decreased in
hhex mutants, whereas vegfc expression in the PCV was clearly
increased (Fig. 2e–h). To test whether the phenotype we observed
in hhex mutants might at least in part be due to the modulation
of the Vegfc/Flt4 signaling pathway, we performed a rescue
experiment by injecting messenger RNA (mRNA) encoding full-
length human FLT4 as previously used in zebraﬁsh18. Confocal
imaging of the trunk vasculature of hhex mutant larvae and
quantiﬁcation of vISVs and thoracic duct (TD) extensions
revealed a partial rescue of vISVs and lymphatic formation after
FLT4 mRNA injection (Fig. 2i–l), indicating that the Vegfc/
Flt4 signaling pathway functions downstream of Hhex. Alto-
gether, these results show that Hhex is a crucial regulator of both
ﬂt4 and vegfc expression in the PCV during angiogenic sprouting.
In addition to its role in blood vessel development, the
VEGFC/FLT4 signaling axis also plays an instructive role during
lymphatic vessel development via activation of the transcription
factor PROX120,21. Given that hhex mutants display strongly
reduced lymphatic formation, we sought to determine whether
lymphatic speciﬁcation was affected in hhex mutants by
immunostaining for Prox1. In wild-type siblings at 36 hpf,
Prox1+ endothelial cells are observed in the dorsal part of the
PCV. In contrast, hhex mutants show a near absence of Prox1+
endothelial cells in the dorsal part of the PCV, suggesting that
hhex mutants lack lymphatic precursors (Fig. 3a–e). To conﬁrm
this result, we analyzed the TgBAC(prox1a:TagRFP) line which at
36 hpf labels lymphatic precursors prior to their migration from
the PCV20. Imaging the trunk vasculature of hhex mutants at 36
hpf conﬁrmed that the number of lymphatic precursors, as
assessed by TagRFP expression, were strongly decreased com-
pared to wild type (Fig. 3f–j).
Cell-autonomous requirement for Hhex in sprouting angio-
genesis. Since hhex is expressed not only in endothelial cells but
also in endodermal cells5,22 and the endoderm has been shown
to be important for sprouting angiogenesis from the PCV in
zebraﬁsh23, we sought to determine in which tissue(s) Hhex was
required for angiogenesis. First, we performed whole-mount
in situ hybridization for hhex expression at 36 hpf, when
sprouting angiogenesis starts from the PCV, and at 48 hpf when
vISVs have formed. At 36 hpf, hhex expression is enriched in
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Fig. 3 Zebraﬁsh hhex mutants lack lymphatic precursors. a–d Whole-mount views of 36 hpf hhex+/+ and hhex−/− embryos immunostained for Prox1
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budding endothelial cells in the PCV (Supplementary Fig. 3a); in
transverse sections, hhex expression is observed in the PCV and
in the ventral wall of the dorsal aorta (Supplementary Fig. 3b). At
48 hpf, hhex is expressed in vISVs and does not appear to be
expressed in aISVs based on in situ analysis (Supplementary
Fig. 3c). These data indicate that hhex is expressed in endothelial
cells during sprouting angiogenesis from the PCV.
To determine whether Hhex regulates its own expression,
we performed whole-mount in situ hybridization for hhex in
hhexs722 mutants at 32 hpf. Interestingly, we observed that
endothelial hhex expression was increased in hhex−/− compared
to wild-type (Supplementary Fig. 4a, b). To test whether
the hhexs722 allele encodes a non-functional protein, we injected
wild-type and mutant hhex mRNA into wild-type zebraﬁsh
embryos at the one-cell to four-cell stage (Supplementary Fig. 4c).
Overexpression of wild-type hhex led to strong developmental
defects when injecting 50 to 200 pg while injection of similar
amounts of hhexs722 mRNA had little effects on embryonic
development (Supplementary Fig. 4c). Altogether, these data
indicate that the hhexs722 allele encodes a non-functional protein
and that hhex can negatively regulate its own expression.
To investigate the requirement of hhex in endothelial cells
to form vISVs and LECs, we generated mosaic animals by
transplanting wild-type Tg(ﬂi1.ep:DsRedEx) donor cells into
TgBAC(etv2:EGFP) hosts derived from hhex+/− incrosses. At
5 dpf, we imaged successfully transplanted larvae and quantiﬁed
both vISV and TD extensions. We observed that transplanted
wild-type endothelial cells were able to contribute to arteries,
veins, and lymphatics in wild-type siblings as well as in mutant
hosts (Fig. 4a, b and Supplementary Fig. 5). Indeed, transplanted
wild-type cells could rescue both vISV and TD formation in hhex
mutants (Fig. 4c, d). Interestingly, wild-type and hhex mutant
cells could be observed in vISVs, suggesting a defect in tip cell
speciﬁcation or behavior in hhex mutant cells. Wild-type tip cells
may thus be sufﬁcient to guide hhex mutant stalk cells and
assemble a mosaic ISV. However, only wild-type cells were
detectable in the TD of hhex mutants hosts, indicating that hhex
is necessary for LEC differentiation.
To further test the endothelial-autonomous requirement of
Hhex in sprouting angiogenesis, we overexpressed hhex in
endothelial cells using the ﬂi1a promoter and visualized the
transgenic cells by fusing tdTomato to the hhex coding sequence
separated by a self-cleaving viral 2A peptide sequence (Fig. 4e).
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We generated a stable transgenic line, Tg(ﬂi1a:tdTomato-2A-
hhex), in which vascular and lymphatic development appeared
to be unaffected (Supplementary Fig. 6) and crossed it to
hhex+/−. Incrosses of Tg(ﬂi1a:tdTomato-2A-hhex); hhex+/− were
used to assess and quantify the rescue of the vascular phenotypes
at 5 dpf. Quantiﬁcation of vISV and TD extensions shows that
hhex expression in endothelial cells was sufﬁcient to rescue both
vISV and TD network formation in hhex mutants (Fig. 4f, g),
thereby conﬁrming the cell-autonomous function of Hhex during
the formation of these structures identiﬁed in the cell transplan-
tation experiments.
To identify additional Hhex target genes, we performed RNA
sequencing on 48 hpf hhex mutant endothelial cells, hhex-
overexpressing endothelial cells, and wild-type endothelial cells
(Fig. 4h). Analysis of gene set enrichments between endothelial
overexpression and mutant conditions pointed to a role for hhex
in lymphatic vessel development (upregulation) and hematopoi-
esis (downregulation) (Supplementary Fig. 7a, b), while compar-
isons between endothelial overexpression and wild-type
conditions pointed to a role for hhex in vascular development
(upregulation) and hematopoiesis (downregulation) (Supplemen-
tary Fig. 7c, d). By comparing endothelial overexpression and
mutant conditions, we also found that the expression of genes
implicated in lymphatic speciﬁcation (prox1a, prox1b, sox18,
nr2f2, mafba) and Flt4 signaling (nrp2a, nrp2b, ﬂt4) was
modulated by Hhex (Fig. 4h and Supplementary Table 1).
Interestingly, endothelial expression of sox18 and nr2f2 did
not seem to be affected in hhex mutants but was upregulated
following Hhex overexpression. The expression of venous
markers including stab1, stab2, ephb4a, ephb4b, and mrc1a did
not appear to be strongly modulated in hhex mutant endothelial
cells, except for that of lyve1b. As Hhex expression has been
shown to be enriched in tip cells24, we also checked different
tip cell markers (apln, aplnrb, adgrl4, esm1, igfbp3, pfkfb3) and
found that hhex overexpression enhanced aplnrb expression
but decreased apln expression. Finally, using quantitative PCR
(qPCR) analysis to further test the RNA sequencing data, we
found that hhex could regulate vegfc, ﬂt4, and prox1a expression
even though hhex overexpression was not sufﬁcient to increase
prox1a expression (Supplementary Fig. 7e). Altogether, these data
indicate that Hhex can cell-autonomously regulate the expression
of genes implicated not only in lymphangiogenesis but also in
sprouting angiogenesis.
HHEX regulates angiogenesis and lymphangiogenesis in
mammals. To determine whether HHEX function in angiogen-
esis and lymphangiogenesis is conserved in mammals, we ﬁrst
took advantage of a previously described Hhex-IRES-Venus
mouse reporter line25. We performed immunostaining on
transverse sections from embryonic (E) day E10.5 embryos
focusing on the CV region where LEC precursors are still located
within the vein and where speciﬁed LECs have already migrated
outside the vein. We observed Hhex reporter expression in
PECAM+ blood endothelial cells as well as in PECAM+/PROX1+
LECs (Fig. 5a–d). We also performed immunostaining on adult
skin and small intestine and observed that the Hhex reporter
is still expressed in blood endothelial cells and LECs (Fig. 5e–l).
These data show that the Hhex reporter is expressed by endo-
thelial cells in both blood and lymphatic vessels, from early
development until adulthood.
To understand the precise function of Hhex during angiogen-
esis and lymphangiogenesis, we reanalyzed the phenotype of the
global Hhex knockout by crossing Hhex ﬂoxed mice (Hhexﬂ/ﬂ)26
with Cmv-cre27 to induce recombination in all tissues. We found
that Hhexmutants were present at a Mendelian ratio at E10.5 and
that this ratio decreased starting at E11.5 as previously described8.
At E10.5, Hhex mutant mice exhibited pericardial edema
and developmental delay (Supplementary Fig. 8a, b). To
characterize the vascular phenotype, we ﬁrst performed whole-
mount PECAM immunostaining on E10.5 embryos and observed
strong vascular defects in the head and in the intersomitic vessels
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in the trunk (Supplementary Fig. 8c–f). We also analyzed the CV
region and found a decreased number of PROX1+ LECs within
the CV and these cells appeared to exhibit weaker PROX1
immunostaining than in wild-types (Supplementary Fig. 8g–i). At
E14.5, only 12.5% of Hhex mutants could be recovered (mostly as
dead or resorbed embryos), and the few surviving Hhex mutants
presented strong vascular defects and blood-ﬁlled lymphatics
(Supplementary Fig. 7j, k).
As the strong vascular defects we observed in Hhex mutants
can affect the number of lymphatic precursors, we decided to
cross Hhexﬂ/ﬂ with Tie2-cre mice28 which carry a cre transgene
active in the blood islands at early stages and targeting both
endothelial and hematopoietic cells29. No Tie2-cre Hhexﬂ/ﬂ
animals were recovered at birth, suggesting that mice lacking
Hhex in Tie2-expressing cells die during embryogenesis. At E10.5,
Tie2-cre Hhexﬂ/ﬂ embryos were recovered at a Mendelian ratio
and, similarly to what was observed with the global Hhex
mutants, this ratio decreased starting at E11.5. Tie2-cre Hhexﬂ/ﬂ
embryos exhibited pericardial edema and developmental delay
(Fig. 6a). Similarly, Flt4 mutant embryos started to die from
E10.5 due to severe cardiovascular defects and exhibited yolk
sac vasculature defects, pericardial edema, and developmental
delay30. We performed whole-mount FLT4 immunostaining on
E10.5 embryos and observed that Tie2-cre Hhexﬂ/ﬂ embryos
exhibited a strong decrease in FLT4 immunostaining notably
in the intersomitic vessels (Fig. 6b, c), possibly explaining the
vascular phenotype. To further characterize the vascular pheno-
type, we also performed whole-mount PECAM immunostaining
on E10.5 embryos and observed some vascular branching defects
in the head (Fig. 6d–f).
The VEGFC/FLT4/PROX1 signaling axis has been shown to
regulate the number of LECs in a dose-dependent manner21,31,32.
To investigate whether HHEX affects the number of LECs, we
quantiﬁed the number of PROX1+ cells in the CV region. Tie2-
cre Hhexﬂ/ﬂ mutants contained fewer PROX1+ endothelial cells
in the CV compared to wild-type siblings (Fig. 6g–i). Importantly,
and as observed in global Hhex−/− embryos, these LECs
were mostly within the vein and rarely outside. As decreased
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expression levels of Flt4 and Prox1 have been shown to trigger
the same phenotype, these results suggest a migration defect in
addition to the observed reduction in the number of LECs. At
E14.5, the percentage of Tie2-cre Hhexﬂ/ﬂ embryos recovered was
below the expected Mendelian ratio (around 15% instead of the
expected 25%), indicating that some Tie2-cre Hhexﬂ/ﬂ embryos
die at earlier stages. Tie2-cre Hhexﬂ/ﬂ embryos alive at this stage
exhibited severe lymphatic defects with edema and blood-ﬁlled
lymphatics (Fig. 7a, c, e-f). Moreover, whole-mount LYVE1
immunostaining revealed that Tie2-cre Hhexﬂ/ﬂ embryos exhibit
defects in the superﬁcial lymphatic vasculature including a
reduction in the number of lymphatic vessels (Fig. 7b, d). We
also examined the effects of deleting Hhex in Tie2-Cre-expressing
cells on the blood and lymphatic vasculature using the dorsal
skin model. At E14.5, LECs sprout and migrate towards the
dorsal midline to form a stereotypical network33. Whole-mount
immunostaining of the embryonic mouse skin with PECAM
and NRP2 antibodies showed that both blood and lymphatic
vascular networks were strongly affected in Tie2-cre Hhexﬂ/ﬂ
embryos compared to Hhexﬂ/ﬂ (Fig. 7g–j). Interestingly, lympha-
tic vessels in Tie2-cre Hhexﬂ/ﬂ mutants displayed decreased
intensity of NRP2 immunostaining compared to wild-type.
In order to investigate the role of Hhex during lymphatic
development, we crossed Hhexﬂ/ﬂ with Prox1-creERT2, a
tamoxifen-inducible cre recombinase expressed in LECs34.
Tamoxifen delivery from E10.5 to 12.5 to delete Hhex in
LECs after their speciﬁcation resulted in edema and blood-
ﬁlled lymphatics at E16.5 (Fig. 8a–d). Additionally, 10%
of Prox1-creERT2 Hhexﬂ/ﬂ embryos were found dead at this stage.
Whole-mount immunostaining of the embryonic mouse skin
with PECAM and NRP2 antibodies showed that the blood
vascular network was not affected in Prox1-creERT2 Hhexﬂ/ﬂ
embryos, while the lymphatic network was clearly affected
(Fig. 8e–h). The lymphatic vessels were shorter, wider, and
exhibited fewer branches in mutants compared to wild-types
(Fig. 8i–k). These results show that Hhex is important for
the establishment of the lymphatic network during dermal
lymphatic formation. Altogether, we investigated the role of
Hhex during blood and lymphatic vascular development using
global and conditional mouse mutants. The timing of Hhex
recombination as well as the different phenotypes observed in
Hhex−/−, Tie2-cre Hhexﬂ/ﬂ, and Prox1-creERT2 Hhexﬂ/ﬂ embryos
are summarized in Fig. 9.
To test whether the role of HHEX is conserved in humans,
we performed cell culture experiments to knockdown HHEX
in human umbilical vein endothelial cells (HUVECs) (Fig. 10a)
and in human dermal LECs (HDLECs) (Fig. 10b). Similarly to
what we observed in both zebraﬁsh and mouse embryos, decrease
of HHEX expression in HUVECs and HDLECs led to decreased
expression of FLT4 while VEGFC was upregulated (Fig. 10a, b).
Interestingly, HHEX knockdown in HDLECs also led to down-
regulation of PROX1 expression consistent with our observations
in zebraﬁsh and mouse (Fig. 10b).
Using in silico predictions, we identiﬁed putative HHEX
binding sites 2 kb upstream of the FLT4 transcriptional start site,
800 bp upstream of the PROX1 transcriptional start site, and
in the 3′ region of VEGFC. To test whether the transcriptional
changes we observed were a result of direct HHEX binding to
VEGFC, FLT4, and PROX1 regulatory elements or via indirect
routes, we performed chromatin immunoprecipitation (ChIP)
experiments using Myc-HHEX adenovirus transfected in
HUVECs (Fig. 10c). We observed a signiﬁcant enrichment of
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Myc-HHEX at the putative HHEX binding sites upstream of
the PROX1 transcriptional start site (Fig. 10c), suggesting that
PROX1 is a direct transcriptional target of HHEX. In contrast, our
analyses did not show binding of HHEX directly to potential
regulatory regions of FLT4 or VEGFC (Fig. 10c), suggesting that
HHEX regulation of these targets is indirect, or that other HHEX
binding sites are present in distal regions. Altogether, these data
indicate that HHEX regulates the VEGFC/FLT4/PROX1 axis in
zebraﬁsh, mouse, and human endothelial cells.
Discussion
Although the transcriptional networks underlying the development
of the blood and lymphatic vessels have started to become
better described, a complete understanding of these processes
remains a major goal. Here, using a combination of systems
and approaches, we have shown that the transcription factor
HHEX functions upstream of several key players in blood and
lymphatic vessel development, namely those of the VEGFC/FLT4/
PROX1 axis.
The formation of the lymphatic vasculature through the
VEGFC/FLT4/PROX1 axis is an evolutionarily conserved
process across vertebrates. Here, using zebraﬁsh, we showed that
hhex is necessary for venous and lymphatic sprouting from
the PCV. hhex mRNA expression is not restricted to lymphatic
precursors as marked by Prox1 expression, but is observed in
both venous endothelial cells and LECs during sprouting from
the PCV. hhex mutants exhibit unique gene expression changes,
with a strong decrease in ﬂt4 expression coupled to ectopic
expression of vegfc in the PCV. Interestingly, FLT4 over-
expression in zebraﬁsh hhex mutants did not completely
rescue the angiogenic defects. It is possible that the loss of hhex
function affects additional pathways involved in sprouting
angiogenesis from the vein, or that the FLT4 mRNA injections
are not able to provide adequate levels of Flt4 function when
needed. Furthermore, overexpression of hhex in endothelial cells
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increased ﬂt4 expression while vegfc was downregulated. One
possible explanation for these observations is that reduction of
ﬂt4 expression could affect vegfc expression and vice versa.
However, Le Guen et al.19 showed that ﬂt4 level was not affected
in vegfc morphants (and vice versa), thus indicating that Vegfc
and Flt4 do not cross-regulate each other transcriptionally. Thus,
Hhex appears to regulate at the same time and in an opposite
fashion the transcription of genes encoding a growth factor and
its receptor.
HHEX has also been implicated in a number of human
pathologies, with a crucial role in several types of cancer35,36.
HHEX is overexpressed in human acute myeloid leukemia35,
while in breast cancer HHEX functions as a suppressor of tumor
growth and negatively regulates VEGFC37. Additionally, HHEX
expression is upregulated in dermal LECs from type 2 diabetes
patients, suggesting a potential lymphatic role for HHEX in
pathological conditions38.
Our RNA sequencing data suggest that Hhex can negatively
regulate its own expression in endothelial cells. Using in situ
hybridization, we indeed observed that endothelial hhex expres-
sion was increased in hhex mutants. This ﬁnding is consistent
with a recent report in hematopoietic cells39.
PROX1 is one of the key transcription factors driving the fate
and speciﬁcation of LECs in all vertebrates. We found that hhex
mutants lack lymphatic precursors as assessed by Prox1 immu-
nostaining and TgBAC(prox1a:TagRFP) expression. Interestingly,
PROX1 is expressed in many of the same tissues and develop-
mental stages as HHEX, including hepatoblasts22. Here, we show
that HHEX and PROX1 are co-expressed in developing LECs and
that HHEX is necessary for PROX1 mRNA and protein expres-
sion. RNA sequencing data of endothelial cells from whole zeb-
raﬁsh embryos indicate that hhex overexpression does not
increase prox1a expression, suggesting that Hhex co-factors
present in subsets of endothelial cells might be necessary to drive
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prox1 expression. Hhex and Prox1 are also both expressed in
endodermal tissues in zebraﬁsh40 and mouse41 embryos, and it
will be interesting to analyze in detail the expression pattern of
these genes in wild-type and mutant animals to better understand
how these genes regulate and maintain the differentiation of
various cell types including LECs.
Our data show that Hhex is required cell-autonomously in
endothelial cells to promote venous and lymphatic sprouting.
Using transplants to generate genetic mosaics, we found that
tip cells in mutant hosts were always wild-type while hhex
mutant cells could participate in vISV formation, suggesting that
Flt4 signaling is not uniformly required for vISV formation but
only for tip cell identity and behavior. This observation has also
been reported in other sprouting angiogenesis contexts including
Wnt signaling and brain angiogenesis42. Additionally, we
observed that only wild-type cells could be found in the TD
indicating a strict cell-autonomous requirement for Hhex in LEC
formation in zebraﬁsh.
Using different mouse models, we show that Hhex is important
for angiogenesis and lymphangiogenesis. Hhex−/− embryos
exhibit severe developmental defects in blood and lymphatic vessel
development while Hhex deletion in a more speciﬁc cell popula-
tion using the Tie2-cre driver recapitulates the global knockout
phenotype. We found that Tie2-cre Hhexﬂ/ﬂ embryos exhibit a
strong decrease in FLT4 immunostaining at E10.5, possibly
explaining the vascular phenotypes. We also observed a reduced
number of Prox1+ cells within the cardinal vein at E10.5, and
these cells had not moved out of the vessel, thus also suggesting a
migration defect. It has been shown in mouse that reducing Vegfc,
Flt4, or Prox1 function affects lymphatic development through a
feedback loop that controls LEC precursor migration out of the
vein21,43. Therefore, the reduced pool of lymphatic precursors we
observed in Hhex mutants might be explained by the direct reg-
ulation of Prox1 by HHEX, while the migration defects might be
due to the downregulation of Flt4.
Tie2-cre mice have been shown to recombine in endothelial
and hematopoietic cells which could also explain the blood-ﬁlled
lymphatic phenotype we observed at later stages. To identify
the direct effects of Hhex on LECs and avoid early defects in vas-
cular development, we used a speciﬁc lymphatic cre line (Prox1-
creERT2) and found that Hhex recombination caused defects in the
formation of the lymphatics. Importantly, it has been reported
that Prox1-creERT2 is most effective at late embryonic stages
(from E12.5 in the skin)44, suggesting that the phenotype we
observed in the skin is due to a late deletion of Hhex, and may
explain why we observed LEC migration rather than speciﬁcation
defects. Determining the role of Hhex during early lymphangio-
genesis will likely require the use of other cre lines in order to
target earlier time points.
Importantly, our work has identiﬁed HHEX as a crucial
transcriptional regulator of lymphangiogenesis and provides
new insights into the transcriptional regulation of lymphatic
differentiation and homeostasis. Lymphedema, a dysfunction
of lymphatic vessels, has a worldwide incidence of 300 million
cases and almost half of the cases have a genetic origin45.
Yet, only very few causative mutations have been identiﬁed in
these patients, making the identiﬁcation of new candidate
genes or signaling pathways regulating lymphatic development
a crucial research interest46. Notably, most of the genes
implicated in lymphatic pathologies are associated with the
VEGFC/FLT4/PROX1 axis, which is essential for lymphatic
physiology not only during development1,3,31 but also during
tissue regeneration and cancer47. Therefore, the analysis of
additional HHEX targets may help identify novel genetic causes
of lymphedema, and also better modulate lymphatic vessels in
various pathologies.
Methods
Zebraﬁsh husbandry and strains. All zebraﬁsh husbandry was performed
under standard conditions in accordance with institutional (MPG) and
national ethical and animal welfare guidelines. We used the following lines:
TgBAC(etv2:EGFP)ci1 48, Tg(kdrl:NLS-mcherry)is4 49, Tg(kdrl:EGFP)s843 50, Tg(ﬂi1a:
nEGFP)y7 51, and Tg(ﬂi1a.ep:DsRedEx)um13 52, TgBAC(prox1a:KalT4-UAS:
uncTagRFP)nim5 53, and Tg(-5.2lyve1b:DsRed)nz101 54. All experiments were
performed using the hhexs722 allele.
Imaging. Images were acquired using a Nikon SMZ25, a Zeiss Stereo
Discovery V8, a Zeiss LSM780 confocal, or a Zeiss LSM800 confocal after
embryo anesthesia with a low dose of tricaine and immobilization in 2% low-
melting agarose in glass bottom petridishes (MatTek corporation). For time-lapse
imaging, images were acquired using a Zeiss Cell Observer SD microscope.
Embryos were mounted in 0.6% low-melting agarose and kept at 28 °C. Time-lapse
images were recorded every 30 min. Facial lymphatics were measured using the
ZEN software to determine the extent of formation of the different facial
lymphatic vessels55,56.
Generation of hhex mutants. hhex mutants were generated by TALEN muta-
genesis targeting exon 3. TALENs were assembled using the Golden Gate method13
and 100 pg of total capped RNA per TALEN arm was injected into one-cell stage
embryos. The following TAL effector domains RVDs were used: NI NG HD NG
NN NG HD NG HD HD NN HD HD HD NN NI NN and HD NG HD NN HD
NG NN NI NN HD NG NN HD NI NN HD NI NG HD NG.
Both alleles were genotyped by high-resolution melt analysis of PCR products.
The primer sequences can be found in Supplementary Data 1.
Quantiﬁcations. Quantiﬁcation of vISVs and TD extensions was performed across
somites located above the yolk sac extension.
FLT4 mRNA injections. Full-length human wild-type FLT4 cloned into pCS2
plasmid18 was linearized using NotI. FLT4 mRNA was then synthesized using a
mMESSAGE mMACHINE SP6 Kit (Life Technologies) and puriﬁed using an RNA
Clean and Concentrator Kit (Zymo Research). FLT4 mRNA was injected at 300 pg
per embryo at the one-cell stage.
Whole-mount in situ hybridization. For whole-mount in situ hybridization57,
embryos were ﬁxed in 4% paraformaldehyde (PFA) overnight at 4 °C and subse-
quently dehydrated in methanol and stored at −20 °C until needed. In the ﬁrst day,
embryos were rehydrated to phosphate-buffered saline (PBS)/0.1% Tween-20 and
then digested in 10 μg ml−1 proteinase K (Roche) followed by ﬁxation in 4% PFA.
Embryos were pre-incubated with hybridization buffer at 70 °C for 3 h and then
incubated with digoxigenin (DIG)-labeled RNA antisense probes at 70 °C over-
night. The next day, after washing, the embryos were incubated with alkaline
phosphatase-conjugated anti-DIG antibody (Roche) at 4 °C overnight. The last day,
after washing, the signal was visualized with NBT-BCIP staining solution (Roche).
Primer sequences used to generate the probes for hhex, ﬂt458, and vegfc59 can be
found in Supplementary Data 1.
Transplantation experiments. Cells from Tg(ﬂi1.ep:DsRedEx) wild-type donor
embryos were transplanted at mid-blastula stages into host embryos derived from
TgBAC(etv2:EGFP); hhex+/− heterozygous incrosses. Successfully transplanted
embryos were selected and imaged at 5 dpf. Quantiﬁcation of vISVs and TD
extensions was performed across four somites above the yolk sac extension.
Transgenesis. To generate the Tg(ﬂi1a:tdTomato-2A-hhex)bns136 line, tdTomato
was fused to the hhex coding sequence separated by a self-cleaving viral 2A peptide
sequence using Cold Fusion Technology (System Biosciences). To generate the line,
25 pg of Tol2 transposase mRNA and 25 pg of pTol2-ﬂi1a:tdTomato-2A-hhex DNA
were co-injected at the one-cell stage. The primers used for genotyping hhex
mutants in the transgenic endothelial overexpression background can be found in
Supplementary Data 1.
Quantiﬁcation and statistical analysis. No statistical methods were used to
predetermine sample size. The experiments were not randomized. The investiga-
tors were not blinded to allocation during experiments or outcome assessment,
except for the data shown in Figs. 2–4a, b. Representative images were selected
from at least three independent experiments. Statistical analysis was performed
using the GraphPad software. Values are presented as mean ± s.e.m. P values
(*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001) were calculated using Student’s
t-test except for the qPCR (Mann–Whitney nonparametric test) and ChIP
(Bonferroni post hoc) experiments.
Mouse strains. All mice used were on a C57BL/6J background. The Hhexﬂ/ﬂ26,
Tie2-cre28, Prox1-creERT2 34, Cmv-cre27, and Hhex-IRES-Venus25 mouse strains
have been described. To generate Hhex+/− mice, Cmv-cre females were crossed
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with Hhexﬂ/ﬂ males. Mice positive for Cmv-cre were then outcrossed with
C57BL/6J mice to generate Hhex+/− mice. Deletion of the Hhex locus was
conﬁrmed by PCR60. To generate embryos, Hhex+/− males were crossed with
Hhex+l− females. Tie2-cre Hhexﬂ/+ males were crossed with Hhexﬂ/ﬂ females to
generate embryos. The day of vaginal plug observation was considered as
E0.5. Prox1-creERT2 animals were crossed with Hhexﬂ/ﬂ to generate Prox1-creERT2
Hhexﬂ/ﬂ. Cre-mediated recombination was induced at E10.5, 11.5, and 12.5 by
intraperitoneal tamoxifen injection (2.5 mg/25 g at 20 mgml−1). Embryos
were harvested at E16.5 for analysis. All mouse experiments were conducted in
accordance with institutional (MPG) and national ethical and animal welfare
guidelines.
Immunostaining. To perform PROX1 immunostaining23,61, zebraﬁsh
embryos were ﬁxed overnight in 4% PFA, washed in 100% methanol, incubated 1 h
on ice in 3% H2O2 in methanol, washed in 100% methanol, and stored at −20 °C.
Samples were then permeabilized in wash buffer (PBS/0.1% Tween/0.1%Triton),
blocked in 10% goat serum/1% bovine serum albumin in wash buffer
overnight at 4 °C, and incubated with Prox1 antibody (1:100, 102-PA32, Reliatech)
overnight at 4 °C. Samples were then washed ﬁve times with wash buffer,
followed by washes with maleic buffer (150 mM maleic acid/100 mM NaCl/0.001%
Tween-20 pH 7.4), followed by blocking in maleic buffer containing 2%
blocking reagent (Roche) for 3 h at room temperature, then incubated overnight
at 4 °C with goat anti-rabbit IgG–horseradish peroxidase (Abcam, ab6721, 1:1000)
for TSA signal ampliﬁcation. Following washes with maleic buffer and PBS,
samples were incubated for 3 h with TSA Plus Cyanine 5 reaction (Perkin
Elmer) and washed with wash buffer several times over 1–2 days at room
temperature.
To perform whole-mount immunostaining in mouse62, tissues were ﬁxed
overnight in 4% PFA and blocked overnight in blocking buffer (TSA blocking
reagent, Perkin Elmer). Tissues were then incubated for 2 days at 4 °C with
biotinylated antibodies in blocking buffer followed by biotin-streptavidin-
horseradish peroxidase ampliﬁcations using the Vectastain-ABC Kit (Vector labs).
For cryostat sections, E10.5 embryos were ﬁxed overnight in 4% PFA,
cryopreserved with 30% sucrose before immersion in OCT (Tissue-Tek), and
stored at −80 °C. Ten micrometer sections were selected (between the eyes and the
heart) to identify the bilateral cardinal veins and perform quantiﬁcation of LECs.
For the analysis of the dorsal dermal lymphatic network, E16.5 embryos were ﬁxed
for 2 h in 4% PFA before the dorsal skin was dissected and stained. Quantiﬁcation
of skin lymphatic vessels was performed using ImageJ. The antibodies used were
PECAM-1 (1:100, MEC13.3, BD Biosciences), GFP (1:100, GFP-1020, Aves Labs),
LYVE1 (1:100, 103-PA50, Reliatech), FLT4 (1:100, AF743, R&D Systems), and
NRP2 (1:100, AF567, R&D Systems).
Primary cells. HUVECs and HDLECs were obtained from Lonza, cultured with
endothelial growth medium-2 (Lonza), and conﬂuent cells were used at passage 6
or less. qPCR analysis of HUVECs showed very minimal expression of PROX1,
LYVE1, and PDPN.
siRNA-mediated knockdown. Cells were transfected with small interfering
RNAs (siRNAs) using Opti-MEM and Lipofectamine RNAiMAX (Invitrogen)63.
The target sequence of the two siRNAs directed against HHEX mRNA can be
found in Supplementary Data 1.
FACS sorting and RNA sequencing. For isolating endothelial cells from 48 hpf
Tg(kdrl:EGFP) siblings and hhex mutants, embryos were selected based on the
presence or absence of parachordal lymphangioblasts. Embryos were then
rinsed in HBSS (Gibco) followed by dissociation in TrypLE express (Gibco) at
28 °C with repeated pipetting. Endothelial cells were isolated using a BD Aria
sorter and sorted for EGFP+ or EGFP+/tdTomato+ signals (for Tg(kdrl:EGFP);
Tg(ﬂi1a:tdTomato-2A-hhex)). RNA was isolated using the miRNeasy Micro Kit
(Qiagen) combined with on-column DNase digestion (DNase-Free DNase Set,
Qiagen) to avoid contamination by genomic DNA. RNA and library
preparation integrity were veriﬁed with BioAnalyzer 2100 (Agilent) and
LabChip Gx Touch 24 (Perkin Elmer). 6 ng of total RNA was used as input for
SMARTer® Stranded Total RNA-Seq Kit–Pico Input Mammalian Kit
(Clontech). Sequencing was performed on a NextSeq500 instrument (Illumina)
using v2 chemistry, resulting in a minimum of 30M reads per library with 1 × 75 bp
single end setup. The resulting raw reads were assessed for quality, adapter
content, and duplication rates with FastQC (Andrews S. 2010, FastQC: a quality
control tool for high-throughput sequence data, http://www.bioinformatics.
babraham.ac.uk/projects/fastqc). Reaper version 13–100 was used to trim reads
after a quality drop below a mean of Q20 in a window of 10 nucleotides64. Only
reads between 30 and 150 nucleotides were cleared for further analyses. Trimmed
and ﬁltered reads were aligned vs. the zebraﬁsh genome version DanRer10
(GRCz10.87) using STAR 2.4.0a with the parameter “--out-
FilterMismatchNoverLmax 0.1” to increase the maximum ratio of mismatches to
mapped length to 10%65. The number of reads aligning to genes was counted with
featureCounts 1.4.5-p1 tool from the Subread package66. Only reads mapping at
least partially inside exons were admitted and aggregated per gene. Reads
overlapping multiple genes or aligning to multiple regions were excluded.
Differentially expressed genes were identiﬁed using DESeq2 version 1.6267. Only
genes with a maximum Benjamini–Hochberg corrected p value of 0.05, and a
minimum combined mean of ﬁve reads were deemed to be signiﬁcantly differen-
tially expressed. The Ensemble annotation was enriched with UniProt data
(release 06.06.2014) based on Ensembl gene identiﬁers. The gene set enrichment
analysis was performed using Metascape68 (www.metascape.org). The RNA-seq
data can be accessed via the accession code GSE111963 (https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE111963). Validation of modulated genes was
performed by qPCR on dissected trunks in hhex mutants, wild-type siblings, and
Tg(ﬂi1a:tdTomato-2A-hhex) embryos.
Quantitative PCR. Total RNA was isolated using the RNA Micro Kit (Qiagen).
RNA was reverse transcribed using the Transcriptor High Fidelity cDNA Synthesis
Kit (Roche) according to the manufacturer’s instructions. qPCR reactions were
carried out using TaqMan Probe Master or SYBR Green I Master (Roche).
Primer sequences used in this study are provided in Supplementary Data 1.
Chromatin immunoprecipitation. HUVECs (5 × 106 cells per ChIP) were infected
with Adenovirus Myc-HHEX or Adenovirus GFP control virus and ChIP
experiments were done69 using a Myc antibody (CST #9B11, 3 μg/ChIP). qPCR
was performed in quadruplicate. All data were normalized to PRM2 (control).
The control region used is located in chromosome 18 where HHEX should not
bind. Primers used can be found in Supplementary Data 1.
Data availability. The authors declare that all data supporting the ﬁndings of
this study are available within the article and its supplementary information ﬁles
or from the corresponding authors upon reasonable request.
The RNA-seq data have been deposited in the NCBI’s Gene Expression
Omnibus database under accession code GSE111963.
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